by Heparin Calcium is a widely used anticoagulant or blood thinner for cardiovascular protection during surgeries and to treat or prevent conditions such as deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. The global heparin calcium market growth is attributed to the increasing incidence of cardiovascular diseases and associated comorbidities that require surgical interventions. An increasing number of cardiovascular surgeries being performed is expected to drive the demand for heparin calcium.
The global Heparin Calcium Market is estimated to be valued at US$ 1407.91 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The growth of the heparin calcium market is propelled by the increasing use of anticoagulants in cardiovascular surgeries. Cardiovascular diseases remain the leading cause of death globally and there have been significant advancements in cardiovascular surgeries such as coronary bypass surgeries and interventions for treating carotid artery diseases.Patients undergoing such surgeries are prescribed anticoagulants including heparin calcium to prevent the formation of blood clots post-surgery.The rising number of cardiovascular surgeries performed annually requires more heparin calcium, thereby driving the market growth over the forecast period.
SWOT Analysis
Strength: Heparin calcium is widely used as an anticoagulant in medical procedures. It is highly effective in preventing blood clots and related complications.
Weakness: Prolonged use of heparin calcium can increase the risk of bleeding and development of hematomas. It also requires continuous monitoring due to the risk of overdose or underdose.
Opportunity: Increasing prevalence of cardiac diseases and lifestyle-related disorders is driving the demand for anticoagulants like heparin calcium globally. Rising geriatric population also provides new growth avenues.
Threats: Stringent regulatory norms pertaining to approval and manufacturing of heparin drugs could hamper business operations. Expiry of patents of major brands forces companies to invest in R&D to develop differentiated products.
Key Takeaways
The global Heparin Calcium Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The market is estimated to reach a value of US$ 1407.91 Mn in 2023 and projected to grow at a CAGR of 2.7% during the forecast period.
Regional analysis
North America is expected to dominate the global heparin calcium market during the forecast period. This is attributed to the rising prevalence of chronic disorders, growing geriatric population, and the well-established healthcare infrastructure in the region. According to surveys, approximately 60% of heparin consumed globally is in North America.
Key players
Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A. Sanofi and Pfizer Inc capture over 50% of the global market share due to their vast product portfolio and global sales network.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
